Post-surgical ctDNA as a prognostic biomarker for relapse of resected cholangiocarcinoma
BACKGROUND: ctDNA is increasingly used to detect minimal residual disease, however, its sensitivity varies by tumor type. Its utility in CCA remains incompletely defined. METHODS: In this single-institution retrospective study, we evaluated ctDNA using a commercial tumor-informed assay (Signatera), compared with CA19-9, for predicting relapse after surgical resection during postoperative (<90 days) and surveillance (≥90 days) windows. We assessed associations between ctDNA status and clinical features, including resection pathology and sites of radiographic relapse. RESULTS: Of 48 patients with CCA who underwent resection between 2020-2025, 26 (54.2%) experienced relapse (median follow-up 18.3 months). ctDNA positivity during both postoperative and surveillance windows was associated with worse median disease-free survival, whereas CA19-9 was not. During the postoperative window, ctDNA sensitivity was 41.7% and specificity was 85.7% for predicting disease relapse any time post-resection. During the surveillance window, sensitivity was 60.0% and specificity was 90.9%. Landmark analysis for relapse at 1-year for ctDNA collected prior to 90 days had a sensitivity of 83.3% and specificity of 90.0%. Among patients with detectable ctDNA who subsequently developed radiographic relapse, median lead time from first ctDNA positivity to relapse was 34 days (IQR 26-132 days), with a maximum lead time of 292 days. ctDNA performance was higher among patients without perineural or lymphovascular invasion and was most frequently positive in those who developed extrahepatic metastases (n = 10/13, 76.9%). CONCLUSIONS: ctDNA is a specific prognostic biomarker that outperforms CA19-9 for predicting relapse after CCA. However, negative ctDNA results should be interpreted cautiously given modest assay sensitivity.
Authors
- Marco Dal Molin (ORCID: https://orcid.org/0000-0003-1581-3576)
- Dung Thi Le (ORCID: https://orcid.org/0000-0002-2110-7697)
- Matthew Z. Guo (ORCID: https://orcid.org/0000-0003-4741-7463)
- Mari Nakazawa (ORCID: https://orcid.org/0000-0001-6055-8960)
- Kelly J. Lafaro (ORCID: https://orcid.org/0000-0002-7070-7269)
- Marina Baretti (ORCID: https://orcid.org/0000-0003-0125-2405)
- Daniel A. Laheru (ORCID: https://orcid.org/0000-0001-6646-0200)
- Helen Catherine Wilbur (ORCID: https://orcid.org/0000-0001-5330-5084)
- Richard Andrew Burkhart (ORCID: https://orcid.org/0000-0003-1087-0870)
- Eric Scott Christenson (ORCID: https://orcid.org/0000-0001-5261-6083)
- Christopher R. Shubert (ORCID: https://orcid.org/0000-0001-6472-2350)
- Mark M. Yarchoan (ORCID: https://orcid.org/0000-0003-4401-0748)
- Robert Anders
- Linda Ye (ORCID: https://orcid.org/0000-0002-0353-4265)
- William Burns
- Nilofer Saba Azad
- Thanh Nguyen
- Jin He
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1093/oncolo/oyag455
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00